Cargando…

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease

BACKGROUND & AIMS: Experimental evidence indicates that systemic inflammation (SI) promotes liver fibrogenesis. This study investigated the potential link between SI and fibrogenesis in patients with advanced chronic liver disease (ACLD). METHODS: Serum biomarkers of SI (CRP, IL‐6, procalcitonin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simbrunner, Benedikt, Villesen, Ida Falk, Königshofer, Philipp, Scheiner, Bernhard, Bauer, David, Paternostro, Rafael, Schwabl, Philipp, Timelthaler, Gerald, Ramazanova, Dariga, Wöran, Katharina, Stift, Judith, Eigenbauer, Ernst, Stättermayer, Albert Friedrich, Marculescu, Rodrig, Pinter, Matthias, Møller, Søren, Trauner, Michael, Karsdal, Morten, Leeming, Diana Julie, Reiberger, Thomas, Mandorfer, Mattias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Cirrhosis, Liver Failure and Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804351/ https://www.ncbi.nlm.nih.gov/pubmed/35822301 http://dx.doi.org/10.1111/liv.15365

Ejemplares similares

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies
por: Königshofer, Philipp, et al.
Publicado: (2021)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
por: Raeven, Pierre, et al.
Publicado: (2020)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis
por: Perramón, Meritxell, et al.
Publicado: (2022)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers
por: Slack, A J, et al.
Publicado: (2013)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution
por: Pehrsson, Martin, et al.
Publicado: (2022)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease
por: Unger, Lukas W., et al.
Publicado: (2019)

Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis
por: Alsamman, Muhammad, et al.
Publicado: (2017)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Mandorfer, M., et al.
Publicado: (2018)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Guideline-conform statin use reduces overall mortality in patients with compensated liver disease
por: Unger, Lukas W., et al.
Publicado: (2019)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
por: Hartl, Lukas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qsicr176hppdssvmog6mlsf3hm